Critical issues relevant to clinical development of BITC are discussed briefly.
Introduction
Ancient holy writings emphasized the medicinal value of isothiocyanate (ITC)-rich herbs and plants, apart from their use in cooking, for pickling, as natural toothpaste and in massage. The ancient Greeks believed that ITC-rich herbs, such as mustard, had been created by Asclepious, the God of healing, as a gift to mankind. Similarly, sticks from the roots of Salvadora persica, commonly known as Miswak sticks and which contain high levels of ITCs, were used for centuries as a traditional method of cleaning teeth (1) .
Epidemiological studies suggest that consumption of a wide variety of vegetables and fruits is protective against cancers, and there is a consistent inverse association between the consumption of Cruciferae vegetables and risk of cancer at most sites (2, 3) . The protective effect of cruciferous vegetables against cancer has been suggested to be due to their relatively high content of glucosinolates, which store ITCs (3) (4) (5) . For example, broccoli is a rich source of glucoraphanin, a precursor of sulforaphane (SFN), and garden cress is rich in glucotropaeolin, the precursor of benzyl isothiocyanate (BITC). Although more than 100 structurally different glucosinolate precursors of ITCs have been identified in nature, SFN, allyl isothiocyanate (AITC), phenethyl isothiocyanate (PEITC) and BITC have been studied most extensively for their anitcarcinogenic properties and mechanistic actions (5-6).
Even a subtle difference in ITC structure and dose can translate into remarkable divergence in the mechanism of the anticancer effect (3, 7) . Existing evidence from preclinical models is mature enough to warrant translation of selective ITCs into human clinical trials. There is growing evidence that the cancer chemopreventive activities of ITCs are complex and can target multiple mechanisms associated with tumor initiation, promotion, progression, and metastasis (3, 4) . This perspective report will summarize possible mechanisms and recent novel findings about BITC as a potential chemopreventive agent for human clinical trials.
The cancer chemopreventive potential of BITC has been well established in rodents; wherein, it has the ability to inhibit chemically-induced as well as spontaneous cancer development (3, 4, 8, 9 liver, pancreatic and colon tumors (8) (9) (10) . In vivo growth of human cancer cells (mammary, pancreatic, and leukemia) implanted into athymic mice is also retarded by BITC administration (11, 12) . Dietary administration of BITC for 25 weeks markedly suppressed the incidence and burden of mammary hyperplasia and carcinoma in mammary tumor virus (MMTV)-neu female mice (12) . BITC decreased pulmonary metastasis multiplicity and volume of 4T1 murine mammary carcinoma cells injected into the inguinal mammary fat pads of syngeneic female BALB/c mice (13) . In addition to the animal studies, a great deal of information exists on in vitro anticarcinogenic effects of BITC in a wide variety of tumor cell lines derived from different organ sites (14) .
Pharmacokinetic studies suggest that low µM concentrations of BITC are sufficient for tumor inhibitory activities (14) . BITC accumulates rapidly in cancer cells and is conjugated with intracellular thiols, particularly glutathione (GSH) and cysteine (3). After ingestion of BITC by human volunteers, the N-acetyl cysteine (NAC) conjugate, representing more than 50% of the initial dose, was excreted rapidly in urine, with maximal concentrations evident 2-6 hours after dosing (15) . Although the biological effects of NAC conjugates of ITCs are not fully understood, these agents have proven to be effective chemopreventive agents in rodent models (3, 4, 15) . Recently, stable reaction products of ITCs with albumin and hemoglobin have been identified (16) , and while detailed pharmacokinetic analysis of BITC remains to be established, existing evidence supports association of human physiological ITC dose levels with cancer chemoprevention effects in rodent models.
Mechanisms of Action of ITCs/BITC
Prevention of cancer initiation by ITCs may involve modulation of carcinogen metabolism through inhibition of Phase I enzymes, or induction of Phase II enzymes, or both (14) . BITC and GSH conjugates of BITC were found to inhibit dealkylation of pentoxyresorufin and ethoxyresorufin in liver microsomes, reactions predominantly mediated by cytochrome p450 (CYP)2B1, CYP1A1/1A2 and CYP2E1, as well as by human CYP2B6 and CYP2D6 (3, 8, 17) . Interestingly, CYP2B1 is one of the isozymes butanone (NNK) (18) . Induction of Phase II enzymes is another mechanism by which chemopreventive agents effectively detoxify and eliminate carcinogens before they act as genotoxic agents. Administration of BITC in the diet (0.5%, w/w) for 2 weeks resulted in an increase in activity of the phase II enzyme quinone reductase (QR) in the lung, kidney, urinary bladder, and colon of female CD-1 mice (4, 8) . The BITC-mediated increase in glutathione transferase (GST) activity in liver and forestomach (19) and the intracellular accumulation GSH in mouse skin papilloma cells correlated with QR activity (20) . In summary, BITC treatment modulates carcinogen metabolism by inhibition of BITC-induced apoptosis has been documented in cultured (24) (25) (26) (27) as well as in xenografted cancer cells (13, 21) . Execution of BITC-Induced apoptosis likely depends on both mitochondrial and death receptor pathways (21) . Though the exact mechanism by which BITC causes apoptosis has been the topic of intense research in the past decade, it is now clear that BITC has the ability to target multiple pathways leading to induction of apoptosis. Key mechanisms in BITC-induced apoptosis include ROS production due to inhibition of mitochondrial respiration, ERK/Akt and forkhead box of the exact mechanisms involved in the divergent chemopreventive effects requires further investigation, Available data suggest that unanticipated adverse effects were associated with high dosages of the ITCs; however, the adverse effects occurred at doses that are several-fold higher than the normal physiological doses. In that context, it is noteworthy that the studies by Kim, et al. (30) showed significant chemopreventive effects at low dose levels corresponding to human exposure levels. A second issue that needs to be addressed is establishment of a formulation of pure BITC suitable for clinical investigation. Third, comprehensive pharmacokinetic data for BITC still are lacking. Finally, suitable biomarker(s) predictive of response are needed for pilot clinical investigations and prior to clinical trials with cancer incidence as the primary end point, which require substantial resources and thousands of subjects.
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